E-LIB Suche - Ergebnisse für: Papp, KA

1

Bimekizumab for the Treatment of Moderate to Severe Plaque ..:

Papp, KA ; Lebwohl, M ; Gottlieb, AB...
SKIN The Journal of Cutaneous Medicine. 5 (2021) 1 - p. s18 , 2021

Link: https://doi.org/10.25251..

2

Bimekizumab Efficacy and Safety versus Adalimumab in Patien..:

Warren, RB ; Blauvelt, A ; Bagel, J...
SKIN The Journal of Cutaneous Medicine. 5 (2021) 1 - p. s15 , 2021

Link: https://doi.org/10.25251..

3

Bimekizumab Safety in Patients with Moderate to Severe Psor..:

Reich, K ; Blauvelt, A ; Lebwohl, M...
SKIN The Journal of Cutaneous Medicine. 5 (2021) 1 - p. s21 , 2021

Link: https://doi.org/10.25251..

4

Maintenance of Response With Guselkumab for up to 3 Years' ..:

Griffiths, CEM ; Papp, KA ; Song, M...
SKIN The Journal of Cutaneous Medicine. 2 (2018) - p. S90 , 2018

Link: https://doi.org/10.25251..

5

Dose Response and Pharmacokinetics of Tofacitinib (CP‐690,5..:

Tan, H ; Gupta, P ; Harness, J...
CPT: Pharmacometrics & Systems Pharmacology. 2 (2013) 5 - p. 1-8 , 2013

Link: https://doi.org/10.1038/..

6

PSY42 USTEKINUMAB REDUCES ITCH, BODILY PAIN, AND FATIGUE IN..:

Lebwohl, M ; Papp, KA ; Han, C...
Value in Health. 12 (2009) 3 - p. A138 , 2009

Link: https://doi.org/10.1016/..

7

PSS60 DERMATOLOGY LIFE QUALITY INDEX IS MORE SENSITIVE THAN..:

Lebwohl, M ; Schenkel, B ; Han, C..
Value in Health. 11 (2008) 6 - p. A628 , 2008

Link: https://doi.org/10.1016/..

8

PSS41 USTEKINUMAB SIGNIFICANTLY IMPROVES HEALTH-RELATED QUA..:

Lebwohl, M ; Schenkel, B ; Han, C...
Value in Health. 11 (2008) 6 - p. A622 , 2008

Link: https://doi.org/10.1016/..

9

Deucravacitinib in Moderate to Severe Psoriasis: Clinical a..:

Thaci, D ; Strober, B ; Gordon, KB...
issn:2193-8210. , 2022

Link: http://hdl.handle.net/11..

10

GUSELKUMAB IN PSORIASIS PATIENTS WITH A HISTORY OF MALIGNAN..:

Blauvelt, A ; Thaçi, D ; Papp, KA...
issn:0560-2076. , 2022

Link: http://hdl.handle.net/11..

11

Maintenance of clinical response and consistent safety prof..:

Reich, K ; Griffiths, CEM ; Gordon, KB...
issn:0190-9622. , 2020

Link: http://hdl.handle.net/11..

12

Improvement in Patient-Reported Outcomes (Dermatology Life ..:

Armstrong, AW ; Reich, K ; Foley, P...
issn:1175-0561. , 2019

Link: http://hdl.handle.net/11..

13

Continuous dosing versus interrupted therapy with ixekizuma..:

Blauvelt, A ; Papp, KA ; Sofen, H...
qt0ws2g80h. , 2017

Link: https://escholarship.org..

14

A Randomized, blinded assessor study to Evaluate the efFIca..:

Papp, KA ; Barber, K ; Bissonnette, R...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC. , 2015

Link: http://www.ncbi.nlm.nih...

15

Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against L..:

Szarewski, A ; Skinner, SR ; Garland, SM...
issn:0022-1899. , 2013

Link: http://hdl.handle.net/11..